期刊
LANCET
卷 381, 期 9883, 页码 2109-2117出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(13)60104-X
关键词
-
资金
- ORVACS by Foundation Bettencourt Schuller
- European Union [223131]
- Spanish Ministry of Science and Innovation [SAF2010-21224]
- Catalan HIV Vaccine Development Programme (HIVACAT)
- Department of Veterans Affairs
- National Institutes of Health [AI080193, AI69432, AI047745, AI74621, AI306214, AI096113, K24 AI069994]
- Delaney AIDS Research Enterprise (DARE) [U19AI096109]
- ICREA Funding Source: Custom
Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据